Table 1.
Key WNT pathway inhibitors in clinical trials.
| Drugs | Target | Modality | Stage | Identifier | Indication |
|---|---|---|---|---|---|
| Ventictumab | FZD1,2,5,7,8 | Monoclonal antibody | Phase 1 |
NCT01973309 NCT01345201 NCT01957007 NCT02005315 |
Breast, Pancreatic and Solid tumors |
| Ipafrecept | FZD8 ligands | Recombinant fusion protein | Phase 1 |
NCT01608867 NCT02069145 NCT02092363 |
Ovarian, Pancreatic, Hepatocellular and Solid tumors |
| 90Y-OTSA101 | FZD10 | Antibody-radioactive isotope conjugate | Phase 1 | NCT01469975 | Synovial sarcomas |
| WNT974 | PORCN | Small molecule | Phase 2 |
NCT02649530 NCT01351103 NCT02278133 NCT02050178 |
Head and Neck; Pancreatic, colorectal and Solid tumors |
| ETC-159 | PORCN | Small molecule | Phase 1 | NCT02521844 | Solid tumors |
| CGX-1321 | PORCN | Small molecule | Phase 1 |
NCT03507998 NCT02675946 |
Solid tumors |
| PRI-724 | β-Catenin /CBP |
Small molecule | Phase 2 |
NCT02413853 NCT01764477 NCT01302405 NCT01606579 |
AML, CML and Solid tumors |
| Cirmtuzumab | ROR1 | Monoclonal antibody | Phase 2 |
NCT03088878 NCT02776917 NCT02222688 NCT02860676 |
Breast cancers, Lymphoma |
| VLS-101 | ROR1 | Antibody-drug conjugate | Phase 2 |
NCT03833180 NCT04504916 |
TNBC, NSCLC and Breast cancers |
| NBE-002 | ROR1 | Antibody-drug conjugate | Phase 2 | NCT04441099 | Advanced solid tumors |